The Benefits of High Relaxivity for Brain Tumor Imaging: Results of a Multicenter Intraindividual Crossover Comparison of Gadobenate Dimeglumine with Gadoterate Meglumine (The BENEFIT Study).

BACKGROUND AND PURPOSE: Gadobenate dimeglumine (MultiHance) has higher r1 relaxivity than gadoterate meglumine (Dotarem) which may permit the use of lower doses for MR imaging applications. Our aim was to compare 0.1- and 0.05-mmol/kg body weight gadobenate with 0.1-mmol/kg body weight gadoterate for MR imaging assessment of brain tumors. MATERIALS AND METHODS: We performed crossover, intraindividual comparison of 0.1-mmol/kg gadobenate with 0.1-mmol/kg gadoterate (Arm 1) and 0.05-mmol/kg gadobenate with 0.1-mmol/kg gadoterate (Arm 2). Adult patients with suspected or known brain tumors were randomized to Arm 1 (70 patients) or Arm 2 (107 patients) and underwent 2 identical examinations at 1.5 T. The agents were injected in randomized-sequence order, and the 2 examinations were separated by 2-14 days. MR imaging scanners, imaging sequences (T1-weighted spin-echo and T1-weighted high-resolution gradient-echo), and acquisition timing were identical for the 2 examinations. Three blinded readers evaluated images for diagnostic information (degree of definition of lesion extent, lesion border delineation, visualization of lesion internal morphology, contrast enhancement) and quantitatively for percentage lesion enhancement and lesion-to-background ratio. Safety assessments were performed. RESULTS: In Arm 1, a highly significant superiority (P < .002) of 0.1-mmol/kg gadobenate was demonstrated by all readers for all end points. In Arm 2, no significant differences (P > .1) were observed for any reader and any end point, with the exception of percentage enhancement for reader 2 (P < .05) in favor of 0.05-mmol/kg gadobenate. Study agent-related adverse events were reported by 2/169 (1.2%) patients after gadobenate and by 5/175 (2.9%) patients after gadoterate. CONCLUSIONS: Significantly superior morphologic information and contrast enhancement are demonstrated on brain MR imaging with 0.1-mmol/kg gadobenate compared with 0.1-mmol/kg gadoterate. No meaningful differences were recorded between 0.05-mmol/kg gadobenate and 0.1-mmol/kg gadoterate.

Association between annular tears and disk degeneration: a longitudinal study.

BACKGROUND AND PURPOSE: Annular tears and nuclear degeneration often occur concurrently, but their temporal association remains unknown. The purpose of this study was to assess whether annular tears precede nuclear degeneration and whether the evolution of nuclear degeneration is affected by presence of annular tears. MATERIALS AND METHODS: From our radiology report data base, 46 patients with back pain were identified, each with 2 previously obtained lumbar spine MR imaging examinations in the absence of any spinal intervention. Two neuroradiologists evaluated intervertebral disks between the T12 and S1 segments in a random blinded fashion. Hyperintense foci within the anulus were noted to diagnose annular tears. The signal intensity of disks was graded on an ordinal scale, and overall degeneration, on the scale of Pfirrmann et al. Mean signal-intensity and degeneration grades were calculated for disks with and without annular tears, and differences were tested for statistical significance. Mean changes in these grades on follow-up studies were also calculated and compared for 2 groups. RESULTS: The study included 13 men and 33 women, with a mean age of 53.6 +/- 15.2 years (range, 20-88 years). The mean interval between the imaging studies was 31.8 months. Annular tears were seen in 203 of 276 (73.5%) disks. Twenty-one of these had normal central signal intensity. Compared with disks without annular tears, disks with annular tears demonstrated significantly higher degeneration grades and a higher change in these grades on follow-up. CONCLUSIONS: Annular tears occur in the early stages of disk degeneration and are associated with a faster subsequent nuclear degeneration.

Contrast-enhanced MR imaging of brain lesions: a large-scale intraindividual crossover comparison of gadobenate dimeglumine versus gadodiamide.

BACKGROUND AND PURPOSE: The higher relaxivity of gadobenate dimeglumine compared with gadodiamide is potentially advantageous for contrast-enhanced brain MR imaging. This study intraindividually compared 0.1-mmol/kg doses of these agents for qualitative and quantitative lesion enhancement. MATERIALS AND METHODS: Adult patients with suggested or known brain lesions underwent 2 identical MR imaging examinations at 1.5T, one with gadobenate dimeglumine and the other with gadodiamide. The agents were administered in randomized order separated by 3-14 days. Imaging sequences and postinjection acquisition timing were identical for the 2 examinations. Three blinded readers evaluated images qualitatively for diagnostic information (lesion extent, delineation, morphology, enhancement, and global preference) and quantitatively for contrast-to-noise ratio (CNR). RESULTS: One hundred thirteen of 138 enrolled patients successfully underwent both examinations. Final diagnoses were intra-axial tumor, metastasis, extra-axial tumor, or other (47, 27, 18, and 21 subjects, respectively). Readers 1, 2, and 3 demonstrated global preference for gadobenate dimeglumine in 63 (55.8%), 77 (68.1%), and 73 (64.6%) patients, respectively, compared with 3, 2, and 3 patients for gadodiamide (P < .0001, all readers). Highly significant (P < .0001, all readers) preference for gadobenate dimeglumine was demonstrated for all qualitative end points and for CNR (increases of 23.3%-34.7% and 42.4%-48.9% [spin-echo and gradient-refocused echo sequences, respectively] for gadobenate dimeglumine compared with gadodiamide). Inter-reader agreement was good for all evaluations (kappa = 0.47-0.69). Significant preference for gadobenate dimeglumine was demonstrated for all lesion subgroup analyses. CONCLUSION: Significantly greater diagnostic information and lesion enhancement are achieved on brain MR imaging with 0.1-mmol/kg gadobenate dimeglumine compared with gadodiamide at an equivalent dose.

Neuropathology for the neuroradiologist: plaques and tangles.

Histologically identified intracellular and extracellular inclusions and structures often provide a tissue diagnosis of a specific disease process. Moreover, these deposits may provide clues about the pathogenesis of the disease in which they are found. Two distinctive structures seen within the brains of patients clinically diagnosed with dementia of the Alzheimer type are extracellular plaques and intracellular neurofibrillary tangles. The purpose of this report is to review the significance of plaques and neurofibrillary tangles in the context of Alzheimer disease.

Neuropathology for the neuroradiologist: Antoni A and Antoni B tissue patterns.

Histologic patterns of cellular architecture often suggest a tissue diagnosis. Distinctive histologic patterns seen within the peripheral nerve sheath tumor schwannoma include the Antoni A and Antoni B regions. The purpose of this report is to review the significance of Antoni regions in the context of schwannomas.

Neuropathology for the neuroradiologist: fluorescence in situ hybridization.

SUMMARY: Fluorescence in situ hybridization is a molecular cytogenetic technique that localizes segments of DNA within tumor cells by using dyes that are visible with a fluorescent microscope. The technique has proved useful in typing a variety of tumors such as oligodendrogliomas and in understanding the genetic forces driving oncogenesis.

Neuropathology for the neuroradiologist: palisades and pseudopalisades.

Histologic patterns of cellular architecture often suggest a tissue diagnosis. One distinctive histologic pattern seen within some tumors of the nervous system is the palisade. The purpose of this report is to review the significance of palisades and pseudopalisades in the context of such tumors as schwannomas and glioblastomas.

Neuropathology for the neuroradiologist: Rosenthal fibers.

Distinctive intracellular structures known as inclusions may be occasionally observed on stained tissue preparations and may further suggest a specific diagnosis. Pathologists rely on these findings much as radiologists rely on findings revealed in the gray-scale patterns of densities and intensities on images. Appreciation of these inclusions can enhance the interactions of the neuroradiologist with the neuropathologist and deepen understanding of certain conditions. This report reviews the neuropathologically observed intracellular inclusions known as Rosenthal fibers in the context of Alexander disease and slow-growing tumors such as pilocytic astrocytoma.

Neuropathology for the neuroradiologist: rosettes and pseudorosettes.

The neuropathologic diagnosis of brain tumors entails the microscopic examination of conventional formalin-fixed paraffin-embedded tissue samples surgically removed from a radiographically defined lesion. A preliminary diagnosis is often rendered with frozen sections, though the final or definitive diagnosis usually requires more elaborate studies. Typically, the tissue is first fixed for a minimum of several hours in 10% neutral buffered formalin, processed through a series of dehydrating and clearing reagents, and embedded in a hardening wax, such as paraffin. The latter enables the tissue to be thinly sliced with a microtome, transferred to a glass slide, and then stained with dyes such as hematoxylin-eosin (H&E) that contrast the different cellular elements. Pathologists rely on visual clues such as pattern recognition when examining the stained tissue with a microscope, much as radiologists rely on gray-scale patterns of densities and intensities on images. Some histologic patterns of cellular architecture are distinctive if not pathognomonic, whereas others are less specific, but nevertheless considerably narrow the differential diagnosis. The precise biologic bases for some of the observed microscopic patterns are poorly understood, though their recognition remains useful nonetheless. Although more advanced methods of tissue examination--such as histochemical and immunohistochemical profiling, genetic analysis, and electron microscopy--have been developed, the microscopic review of H&E-stained material remains a critical component of tumor diagnosis.

Spasticity, strength, and gait changes after surgery for cervical spondylotic myelopathy: a case report.

STUDY DESIGN: A case report with repeated measures is presented. OBJECTIVE: To describe an objective method for evaluating changes in upper- and lower-extremity spasticity and strength, as well as temporal and kinematic gait variables, after surgical intervention for cervical spondylotic myelopathy. SUMMARY OF BACKGROUND DATA: Degenerative cervical spinal disease is a common disorder, with some form of spondylosis demonstrated radiographically in more than 80% of those older than 55 years. Normative pre- and postoperative objective data quantifying spasticity, strength, and gait do not exist. METHODS: A 65-year-old woman underwent C2-C3 anterior cervical discectomy and fusion for progressive myelopathy secondary to a spondylosis and disc herniation. The measure for spasticity and strength at the ankles and elbows and a gait analysis were collected before surgery and at 11 days, 3 and 6 months after surgery. Spasticity and strength were assessed using a dynamometer, and a six-camera video system was used to record the gait. RESULTS: Preoperative left elbow flexor spasticity was more than 10 times greater than the values for the able bodies. It was reduced to normal levels after surgery. Substantial presurgery weakness was present in the elbow flexors and extensors bilaterally. Elbow extensor strength was at able-body levels after surgery. Gait speed was 57% of the able-body level before surgery and 78% of the able-body level 6 months after surgery. CONCLUSIONS: This case study demonstrated the role of biomechanics in characterizing impairments associated with cervical spondylosis and its surgical intervention. Measures for spasticity, strength, and gait taken before and after surgery indicated a favorable outcome. This report provides a foundation for the continued use of biomechanical methods to measure changes in function and impairments associated with surgical intervention of cervical spine disorders.

Headache in the HIV patient: a review with special attention to the role of imaging.

Headache is one of the most commonly encountered neurologically related complaints in HIV patients. The authors review the relationship between HIV infection and headache and discuss the role of neuroimaging in this select patient group.

Evaluation of a reduced MR imaging sequencing protocol in adult patients with stroke.

PURPOSE: To compare a reduced (three-sequence) magnetic resonance (MR) imaging protocol with a full (eight- to 10-sequence) MR imaging protocol in adults suspected of having stroke. MATERIALS AND METHODS: Six neuroradiologists interpreted a consecutive sample of 265 MR images in patients suspected of having stroke. Each read reduced-protocol images in a discrete series of 40 patients (one read images in only 15) and corresponding full-protocol images 1 month later (reduced/full protocol). Five of the readers each read images in 10 additional cases, five each as full/full and reduced/reduced protocol controls. kappa values between full and reduced protocols, reader assessment of protocol adequacy, confidence level, and need for additional sequences or examinations were evaluated. RESULTS: In the reduced/full protocol, the kappa value for detecting ischemia was 0.797; and that for detecting any clinically important abnormality, 0.635. Statistically similar kappa values were found with the full/full control design (kappa = 0.802 and 0.715, respectively). The full protocol was judged more adequate than the reduced protocol (2.0 of 5.0 points vs 1.6, P <.001) and generated greater diagnostic confidence (8.6 of 10.0 points vs 8.9, P =.01), less need for additional sequences (2.7 of 6.0 points vs 1.5, P <.001), and more requests for additional examinations (28.4% vs 36.3%). CONCLUSION: Disagreement between interpretations of reduced- and full-protocol images might be attributable to baseline-level intraobserver inconsistency, as demonstrated in control designs. A greater number of sequences did not lead to greater consistency.

Comparison of CT myelography performed in the prone and supine positions in the detection of cervical spinal stenosis.

AIM: To quantify the change in the cross-sectional area of the cervical spinal cord and subarachnoid space (SAS) in the supine neutral vs prone extension positions in patients with myelopathy undergoing cervical CT myelography. MATERIAL AND METHODS: Axial CT myelgrams of 21 myelopathic patients were performed in both the supine neutral and prone extension positions. The SAS and cord cross-sectional areas were then measured at the disk spaces and mid-pedicle levels from C2 to T1 in both the supine and prone positions using a public domain NIH Image program, version 156b18. Mean area measurements in both positions were then compared for each level examined. RESULTS: Mean SAS cross-sectional area in the prone position was notably reduced compared with the supine position at C4-C5 [128.8 mm2 vs 168.1 mm2 (P<.05)], and C5-C6 [98.8 mm2 vs 143.2 mm2 (P<.05)] disk levels. The mean cord cross-sectional area failed to change significantly with positioning. CONCLUSIONS: Prone myelography may demonstrate a greater degree of cervical spine stenosis compared with CT myelography performed in the supine position in myelopathic patients. Imaging with the patient prone with neck extended in both myelography and CTM may improve precision in the results of measurements of the stenotic spinal canal when comparing these two methods. Blease Graham III, C. (2001). Clinical Radiology56, 35-39.

Magnetic resonance imaging in patients with central nervous system pathology: a comparison of OptiMARK (Gd-DTPA-BMEA) and Magnevist (Gd-DTPA).

RATIONALE AND OBJECTIVES: The objective of the two pivotal phase 3 studies was to evaluate the safety and efficacy of OptiMARK (Gd-DTPA-bis(methoxyethylamide) [Gd-DTPA-BMEA]) compared with Magnevist (Gd-DTPA) in magnetic resonance imaging of the central nervous system. METHODS: Two multicenter, randomized, double-blind, parallel group studies were conducted in 395 patients with known or suspected central nervous system pathology. Subjects were randomized to receive a single 0.1 mmol/kg intravenous injection of either Gd-DTPA-BMEA or Gd-DTPA. The safety of Gd-DTPA-BMEA and Gd-DTPA was monitored for up to 72 hours after study drug administration. Precontrast and postcontrast administration magnetic resonance scans were acquired using identical imaging planes and techniques. RESULTS: No deaths or unexpected adverse events were reported in either group. A comparison of adverse events by intensity and relation demonstrated no statistically significant differences between the two groups. Gd-DTPA-BMEA and Gd-DTPA were equivalent with respect to confidence in diagnosis, conspicuity, and border delineation. CONCLUSIONS: Gd-DTPA-BMEA and Gd-DTPA demonstrated comparable efficacy profiles, and the safety profiles were considered similar.

MR imaging of herpes simplex type 1 encephalitis in infants and young children: a separate pattern of findings.

OBJECTIVE: We sought to identify the initial MR findings of herpes simplex encephalitis in infants and young children. CONCLUSION: MR imaging findings of herpes encephalitis in infants and young children appear to differ from those seen in neonates, older children, and adults. Appreciation of this MR imaging pattern coupled with a strong clinical suspicion of herpes helps to ensure the correct diagnosis is made.

Screening CT of the brain determined by CD4 count in HIV-positive patients presenting with headache.

BACKGROUND AND PURPOSE: Few studies have examined HIV-positive patients presenting with uncomplicated headache for clinical variables that might be predictive of those patients who would most benefit from CT. Because of the value of CD4 counts in predicting the relative risk of developing opportunistic infections and neoplasms, we assessed the diagnostic yield of screening CT in HIV-positive patients presenting with headache as sorted by CD4 count. METHODS: We reviewed CT scan results and CD4 counts in patients presenting with headache uncomplicated by altered mental status, meningeal signs, neurologic findings, or symptoms of subarachnoid hemorrhage. For analysis, scans were considered positive or negative and were grouped according to CD4 counts of less than 200 cells/microL, 200 to 499 cells/microL, and equal to or greater than 500 cells/microL. The results were then analyzed using the chi2 test. RESULTS: One hundred seventy-eight HIV-positive patients underwent a total of 204 unenhanced and contrast-enhanced CT examinations. One hundred twenty-eight (62.7%) of the scans were negative, and 76 (37.3%) were positive. Of the positive scans, 58 (76.3%) showed atrophy only and 18 (23.7%) showed mass lesions or white matter lesions. All cases that were positive for mass lesions or white matter lesions occurred in patients with CD4 counts less than 200 cells/microL (P = .04). CONCLUSION: A recent CD4 count provides an important predictor variable when considering performing CT in HIV-positive patients presenting with uncomplicated headache. Performing CT of the head for patients with CD4 counts equal to or greater than 200 cells/microL is of questionable value considering the low prevalence of positive CT findings. For this select group of patients, MR imaging may be more appropriate than CT. Patients with CD4 counts less than 200 cells/microL should undergo CT because of the high prevalence of positive scans.